MyoKardia is a clinical-stage biopharmaceutical company that uses its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of hypertrophic cardiomyopathy and dilated cardiomyopathy. The company's products include MYK-461, an orally administered small molecule to reduce excessive cardiac muscle contractility leading to HCM. The company is committed to creating a culture that's centered on its core values and seeks individuals who can serve as cultural leaders and role models for its values.